Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Urology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Urology

Journal Scan / Research · February 16, 2022

HRQOL in Metastatic Hormone-Sensitive Prostate Cancer

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP
J. Clin. Oncol 2021 Dec 20;[EPub Ahead of Print], MR Stockler, AJ Martin, ID Davis, HM Dhillon, SD Begbie, KN Chi, S Chowdhury, X Coskinas, M Frydenberg, WE Hague, LG Horvath, AM Joshua, NJ Lawrence, GM Marx, J McCaffrey, R McDermott, M McJannett, SA North, F Parnis, WR Parulekar, DW Pook, MN Reaume, S Sandhu, A Tan, TH Tan, A Thomson, F Vera-Badillo, SG Williams, DG Winter, S Yip, AY Zhang, RR Zielinski, CJ Sweeney

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading